Sim racing gained a lot of popularity in recent years, with many more enthusiasts than ever wanting to experience the thrill of racing or driving from the comfort of their homes. Incidentally, Samsung display technologies and sim racing often overlapped, and that’s even more true now that Samsung and Racing Unleashed have entered a new partnership.
Late last month, Samsung Electronics Switzerland and Racing Unleashed announced that they’re joining forces to combine their expertise and technologies for the betterment of the Racing Unleashed ecosystem. As a result, Samsung is now an official partner and display provider.
Samsung displays powering RU’s sim rigs
As part of this new collaboration, Racing Unleashed’s simulator rigs will now boast next-gen Samsung display technologies, whether they have single-screen or multi-screen setups.
In addition, Samsung displays will also be used during Racing Unleashed esports competitions and at racing lounges in Switzerland, Germany, and Spain, where racing enthusiasts can come together to exchange ideas, celebrate, and compete on virtual racing tracks.
Racing Unleashed manufactures carbon fiber simulators in Maranello, Italy, using cutting-edge tech. Their Formula-style sim rigs are designed for racing lounges, amateurs, and pro racers alike.
Neither Samsung nor RU has revealed exactly which Samsung displays will be used for these advanced simulator rigs, but Samsung’s official announcement does tag the Odyssey series.
Judging by the image above shared by RU, some sim rigs are equipped with flat displays while at least one appears to have an ultrawide curved Odyssey monitor.
US drug regulators dropped a bombshell in November 2023 when they announced an investigation into one of the most celebrated cancer treatments to emerge in decades. The US Food and Drug Administration (FDA) said it was looking at whether a strategy that involves engineering a person’s immune cells to kill cancer was leading to new malignancies in people who had been treated with it.
Bruce Levine, an immunologist at the University of Pennsylvania Perelman School of Medicine in Philadelphia who helped to pioneer the approach known as chimeric antigen receptor (CAR) T-cell therapy, says he didn’t hear the news until a reporter asked him for comments on the FDA’s announcement.
“Better get smart about it quick,” he remembers thinking.
Although the information provided by the FDA was thin at the time, the agency told reporters that it had observed 20 cases in which immune-cell cancers known as lymphomas had developed in people treated with CAR T cells. Levine, who is a co-inventor of Kymriah, the first CAR-T-cell therapy to be approved, started jotting down questions. Who were these patients? How many were there? And what other drugs had they received before having CAR-T-cell therapy?
How to supercharge cancer-fighting cells: give them stem cell skills
The FDA has since documented more cases. As of 25 March, the agency had received 33 reports of such lymphomas among some 30,000 people who had been treated. It now requires all CAR-T therapies to carry a boxed warning on the drug’s packaging, which states that such cancers have occurred. And the European Medicines Agency has launched its own investigation. But many of the questions that Levine had in November remain unanswered. It is unclear how many, if any, of the observed cancers came directly from the manipulations made to the CAR T cells. A lot of cancer therapies carry a risk of causing secondary malignancies, and the treated individuals had received other therapies. As Crystal Mackall, a paediatric oncologist who heads the cancer immunotherapy programme at Stanford University in California, puts it: “Do you have a smoking gun?”
Scientists are now racing to determine whether the cellular therapy is driving these cancers or contributing in some way to their development. From the data available so far, the secondary cancers seem to be a rare phenomenon, and the benefits of CAR T cells still outweigh the risks for most prospective recipients. But it’s an important puzzle to solve so that researchers can improve and expand the use of these engineered cells in medicine. CAR-T-cell treatments were once reserved for people who had few other options for therapy. But the FDA has approved several of these treatments as a relatively early, second-line option for lymphoma and multiple myeloma. And some companies are working to expand the therapy’s repertoire to solid tumours, autoimmune diseases, ageing, HIVand more.
Aric Hall, a haematologist at the University of Wisconsin–Madison, says that despite the enthusiasm for CAR-T therapy, the technology is still new. “I used to joke that for the first ten years there were more review articles about CAR T than there were patients who had been treated by CAR T products,” he says. He adds that the risks might be rare, but as CAR-T therapy moves into a bigger pool of patients who aren’t desperately ill, the calculus could change. “The problem is rare risks become a bigger deal when patients have better options.”
Vector safety
Throughout the development of these blockbuster therapies, researchers had reason to think that CAR T cells could become cancerous. CAR-T therapies are personalized — created from a person’s immune cells. Their T cells are extracted and then genetically modified in the laboratory to express a chimeric antigen receptor — or CAR — a protein that targets the T cell to specific cells that they will kill. T cells sporting these receptors are made to multiply and grow in the lab, and physicians then infuse them back into the individual, where they start battling cancer cells. The six CAR-T-cell therapies currently approved in the United States and Europe target antigens on the immune system’s B cells, so they work only against B-cell malignancies — leukaemias, lymphomas and multiple myeloma. But researchers are aiming to develop CAR-T therapies that work on other kinds of cancer, and for other conditions.
The genetic engineering is the step that creates a risk of malignancy. All six FDA-approved CAR-T therapies rely on a retrovirus — typically a lentivirus, such as HIV, or a gammaretrovirus — to ferry the genetic information into the cell. Scientists remove the parts of the viral genome that allow the virus to replicate, making room for the gene they want the virus vector to carry. Once inside a cell, the virus inserts the gene for the CAR into the cell’s genome. But there isn’t a good way to control exactly where the gene goes. If it slips in near a gene that can promote cancer development and activates it, or if it deactivates a tumour-suppressing gene, that boosts the risk of causing a T-cell cancer (see ‘CAR-T concerns’).
This phenomenon, known as insertional mutagenesis, is a risk with most gene therapies. About 20 years ago, for example, groups in London and Paris treated 20 infants who had severe combined immunodeficiency syndrome (SCID) with a gene therapy that used a retrovirus. The therapy worked for most participants, but the retrovirus switched on cancer genes in some. That activation led to leukaemia in five of the participants; four recovered and one died.
As a result, scientists have reworked the vectors to make them safer, ensuring that their genes don’t recombine, for example. The FDA recommends that CAR-T products undergo testing to prove that the vectors cannot replicate. “The scrutiny we’ve been under has been tremendous,” says Hans-Peter Kiem, an oncologist at the Fred Hutchinson Cancer Center in Seattle, Washington, who has studied viral vectors for decades. Many felt confident about using viral vectors in CAR-T therapies, because T cells are difficult to prod towards malignancy, says Marco Ruella, a haematologist at the Perelman School of Medicine. “Truly the general feeling was that, in T cells, lenti- and retroviruses are extremely safe.”
Search for the smoking gun
When the FDA issued its warning in November, it wasn’t clear what specific reports had prompted the agency to act, or whether the link was causal. Levine recruited some of the biggest names in CAR-T therapies to co-write a commentary on the matter and discuss some of the questions he still had1. “I felt — we felt — that it was important to say, ‘Well, let’s take a step back for a minute and see what we really know,’” he says.
Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells
In January, the FDA released more information. In an article in the New England Journal of Medicine, Peter Marks and Nicole Verdun at the FDA’s Center for Biologics Evaluation and Research in Silver Spring, Maryland, revealed that the agency had received 22 reports of leukaemia out of more than 27,000 people treated with various CAR-T therapies2. In three secondary cancers that were sequenced, the agency found that the cancerous T cells contained the CAR gene, “which indicates that the CAR-T product was most likely involved in the development of the T-cell cancer”, the authors wrote.
According to Paul Richards, a spokesperson for the FDA, 11 further reports of secondary cancer have since come in, as of 25 March. None of the extra cases has been confirmed as having the CAR gene, but neither are any of the cases so far definitively CAR-negative, Richards said in an e-mail. In many instances, the agency didn’t have a sample of the secondary cancer to analyse; in others, the genomic analysis isn’t yet complete. He adds that certain reports, specifically those positive for the CAR gene, “strongly suggest” that T-cell cancer should be considered a risk of the therapy.
But even when the CAR gene is present, proving causality can be tricky. In one case study, researchers in Australia described3 a 51-year-old man who had been treated for multiple myeloma with a CAR-T therapy. The treatment was part of a clinical trial of Carvykti, made by Legend Biotech in Somerset, New Jersey, in partnership with the drug giant Johnson & Johnson. The treatment worked to clear his cancer, but five months later he developed an unusual, fast-growing bump on his nose. A biopsy revealed that it was T-cell lymphoma. When the team examined the cancerous cells, they found the gene for the CAR wedged into the regulatory region of a gene called PBX2.
Cutting-edge CAR-T cancer therapy is now made in India — at one-tenth the cost
The finding is provocative, Mackall says, but still not a smoking gun, in her opinion. The researchers found that the cancer cells also carried a mutation often seen in lymphomas, and the person had a genetic variant that put him at increased risk of developing cancer, even without the CAR insertion. It’s likely that the cells harvested to create the therapy contained some pre-cancerous T cells, says Piers Blombery, a haematologist at the Peter MacCallum Cancer Centre in Melbourne, Australia, who leads the diagnostic lab that assessed the tumour samples. Now, the team is looking at samples taken before the therapy to determine whether that’s the case.
Other people who have received Carvykti have developed secondary cancers, too. The FDA’s initial warning focused on T-cell malignancies. But long-term follow-up of participants who’d been in an early trial of Carvykti revealed that 10 out of 97 people developed either myelodysplastic syndrome (a kind of pre-leukaemia) or acute myeloid leukaemia (see go.nature.com/3q8vrym). Nine of them died. As a result, in December 2023, Legend Biotech added language to its boxed warning for Carvykti about the risk of secondary blood cancers.
Craig Tendler, head of oncology clinical development and global medical affairs at Johnson & Johnson Innovative Medicine in Raritan, New Jersey, says that the company looked for the CAR gene in cancer cells from these individuals, but didn’t find it. When the researchers looked at samples taken before the trial participants received treatment, they found pre-malignant cells with the same genetic make-up as the cancer cells. “So, it is likely that, in many of these cases, the prior therapies for multiple myeloma may have already predisposed these patients to secondary malignancy,” Tendler says. Then, it’s possible that the prolonged immune suppression related to the CAR-T treatment process nudged the cells to become cancerous.
Can autoimmune diseases be cured? Scientists see hope at last
When Ruella first saw the FDA warning, he immediately thought back to a 64-year-old man he had treated who, in 2020, developed a T-cell lymphoma 3 months after receiving CAR-T therapy for a B-cell lymphoma. Ruella and his colleagues identified the CAR gene in the biopsy taken from the man’s lymph node4. But it was at such low levels that it seemed unlikely it had integrated into the cancer cells, Ruella says. Instead, the genes could have come from CAR T cells that just happened to be circulating through that lymph node at the time the biopsy was taken. “We thought this was just an accidental finding,” Ruella says.
But after Ruella saw the FDA’s warning, he decided to revisit the case. He and his colleagues went back to a blood sample taken before the person received CAR-T therapy. The team assessed whether T cells with the same T-cell receptor as the lymphoma cells were present before treatment. They were, suggesting that the seeds of the lymphoma pre-dated the therapy. (The low number of cells made further analysis difficult.) Ruella adds that it’s possible the CAR-T treatment produced an inflammatory environment that allowed such seeds to become cancerous. “So this is not something that appears magically out of nowhere,” Ruella says.
Rare outcome
The good news is that these secondary cancers — CAR-driven or not — seem to be rare. After the FDA warning, Ruella and his colleagues also looked back at the files of people who had been treated with commercial CAR-T products at the University of Pennsylvania. Between January 2018 and November 2023, the centre treated 449 individuals who had leukaemias, lymphomas or multiple myeloma with CAR-T therapies4. Sixteen patients (3.6%) went on to develop a secondary cancer. But most of those were solid tumours, not the kind of cancer one would expect to come directly from the treatment. Only five of the treated patients developed blood cancers, and only one of those developed a T-cell cancer.
At the Mayo Clinic in Phoenix, Arizona, haematologist Rafael Fonseca and his colleagues also wondered whether the incidence of secondary cancers in people who had received CAR-T therapy differed from the incidence in those with the same cancers who had not. They combed through a data set containing medical records from 330 million people to find individuals who had been newly diagnosed with multiple myeloma or diffuse large B-cell lymphoma between 2018 and 2022. They then looked at how many of them developed T-cell lymphomas. The prevalence didn’t differ drastically from the 22 cases out of 27,000 people that the FDA had reported. The researchers published their findings on the online newsletter platform Substack (see go.nature.com/3u97s38). “We wanted to get it out as soon as possible because of the timeliness of what was going on,” Fonseca says.
The race to supercharge cancer-fighting T cells
Since the FDA’s warning, Hall has started talking about the possibility of secondary cancers to individuals who are contemplating CAR-T therapy. He presents it as a real risk, but a rare one — and explains that it is dwarfed by the risk posed by their current cancer. “For my late-stage myeloma patient, the main risk is that the CAR T doesn’t work and they die of their myeloma,” he says. Mackall and others agree. “I don’t think anyone believes that this will change practice in any way at the current time,” she adds. “Most cancer therapies can cause cancer. This is one of the paradoxes of our business.”
But what about other diseases? Researchers have already tested CAR T cells as a therapy for the autoimmune condition lupus, with impressive results5. And more clinical trials of these therapies for other autoimmune diseases are likely to follow. If most of the secondary cancers seen in people treated with CAR T cells are related to the litany of treatments they received beforehand, people with these conditions might not all have the same risk. But even if the therapy is driving some cancers, many say the benefits might still be worth the risk. “Autoimmune diseases are not benign diseases,” said Marks in response to an audience question at an industry briefing in January (see go.nature.com/3jpk6qj). “Anyone who’s ever known somebody who’s had lupus cerebritis or lupus nephritis will know that those are potentially lethal diseases.”
CAR T cells also hold promise as a treatment for HIV infection, and a trial to test this idea kicked off in 2022. Researchers are also studying how CAR T cells could be used as a way to curb rejection of transplanted kidneys, or to clear out zombie-like senescent cells that have been implicated in ageing. The possibilities are continuously expanding.
As for whether the benefit of CAR-T therapy outweighs the risk of secondary cancers for these other indications, only time will tell.
Samsung is showcasing its display technology prowess through a new collaboration with Amazon that revolves around its latest addition to its entertainment business portfolio: Culver Post. The latter is a state-of-the-art theatrical post-production studio located in Los Angeles.
Samsung says it has partnered with 424 Post and Harbor to provide advanced display technologies for Amazon’s post-production studio. As a result, Culver Post takes advantage of a 34-foot 8K Samsung The Wall LED (IWA-series) display and DCI-certified 4K Samsung Onyx LED displays.
The right equipment for the job
Culver Post is a full-service post-production studio that should bring unparalleled HDR and SDR mastering capabilities. It offers five stages of theatrical color grading and sound mixing. The first and second stages are outfitted with the Samsung 8K IWA-series The Wall and Onyx LEDs, respectively.
Although both solutions are based on LED technology, The Wall (IWA series) is ideal for both HDR and SDR color grading, whereas Onyx is a cinema LED display ideal for HDR color grading and mastering.
Onyx is the world’s first DCI-certified cinema LED display, and over the past few years, it was adopted by dozens of theaters in more than 120 countries. In January, it finally arrived in Germany for the first time and debuted at the Lamm-Lichtspiele cinema arthouse cinema in Erlangen.
As for Amazon’s Culver Post in Los Angeles, Samsung’s LED solutions ensure that filmmakers and creators can have the best editing and viewing experience. Each Culver Post stage also features Meyer Sound Ultra Reflex sound systems with Dolby Atmos. In addition, each stage has enough room for roughly 50 guests, including cinematographers, colorists, and editors.
These technologies combined allow entire production teams to experience a cinematic working environment and bring the spirit of collaboration to mastering and post-production.
Image Credit: Samsung
Join SamMobile on social media to get instant Samsung news updates, in-depth reviews, hot deals, and more.
T cells (pink) attack a cancer cell (yellow) in this scanning electron micrograph image.Credit: Steve Gschmeissner/SPL
A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as chimeric antigen receptor (CAR) T-cell therapy that was pioneered in the United States. CAR-T therapies are used mainly to treat blood cancers and have burgeoned in the past few years. The Indian CAR-T therapy costs one-tenth that of comparable commercial products available globally.
A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000. The first CAR-T therapy was approved in the United States in 2017, and commercial CAR-T therapies currently cost between $370,000 and $530,000, not including hospital fees and drugs to treat side effects. These treatments have also shown promise in treating autoimmune diseases and brain cancer.
India’s drug regulator approved NexCAR19 for therapeutic use in India in October. By December, ImmunoACT was administering the therapy to paying patients, and it is now treating some two-dozen people a month in hospitals across the country.
“It’s a dream come true,” says Alka Dwivedi, an immunologist who helped to develop NexCAR19 and is now at the US National Cancer Institute (NCI) in Bethesda, Maryland. Her voice becomes tender as she describes seeing the first patient’s cancer go into remission. These are people for whom all other treatments have failed, says Dwivedi. “They are getting cured.”
“It’s very positive news,” says Renato Cunha, a haematologist at the Grupo Oncoclínicas in São Paulo, Brazil. He says the Indian product could pave the way for making advanced cellular therapies accessible to other low- and middle-income countries. “Hope is the word that comes to mind.”
The product is also a reality check for researchers in high-income countries, says Terry Fry, an immunologist and paediatric oncologist at the University of Colorado Anschutz Medical Campus in Denver, who has advised the researchers involved in setting up ImmunoACT. “It lights a little fire under all of us to look at the cost of making CAR-T cells, even in places like the United States.”
Tremendous need
CAR-T therapy involves taking someone’s blood and isolating immune components known as T cells. These are genetically modified in the laboratory to express a receptor, known as a CAR, on their surface. This helps the immune cells to find and kill cancer cells. The engineered cells are then mass-produced and infused back into the patient, in whom they proliferate and get to work.
The race to supercharge cancer-fighting T cells
Data on demand for these therapies in India are limited, but one study looking at a specific form of leukaemia found that up to 15 people in 100,000 are diagnosed with the disease, half of whom relapse within two years of receiving treatment, such as chemotherapy, and who subsequently choose palliative care1. There is a “tremendous patient need”, says Nirali Shah, a paediatric oncologist at the NCI, who is also an academic collaborator of the researchers at ImmunoACT.
NexCAR19 is similar to its US counterparts, yet distinct in key ways. Like four of the six CAR-T therapies approved by the US Food and Drug Administration (FDA), it is designed to target CD19, a marker found on B-cell cancers2. However, in existing commercial therapies, the antibody fragment at the end of a CAR is typically from mice, which limits its durability because the immune system recognizes it as foreign and eventually eliminates it. Therefore, in NexCAR19, Dwivedi and her colleagues added human proteins to the mouse antibody tips.
Lab studies showed that the ‘humanized’ CAR had comparable antitumour activity to a mouse-derived one and induced the production of lower levels of proteins called cytokines2. This is important, because some people with cancer who receive CAR-T therapy experience an extreme inflammatory reaction known as cytokine-release syndrome, which can be life-threatening.
Trial data
Early-stage clinical trials for NexCAR19 in adults with different forms of lymphoma and leukaemia, showed that in 19 of the 33 people who received the therapy, the tumours had completely disappeared at the one-month follow-up3. The tumours in another four people had shrunk by half — achieving an overall response rate of 70%. Trial participants will be followed for at least five years.
“Whether this will hold or not is something only time will tell,” says Hasmukh Jain, a medical oncologist at Tata Memorial Centre in Mumbai, who led the trials.
Natasha Kekre, a haematologist at the Ottawa Hospital, points out that the results are based on a small number of participants with a range of blood cancers, which makes it difficult to assess the treatment’s efficacy for specific cancers.
Only two of the participants experienced more severe forms of cytokine-release syndrome, and none had neurotoxicities, another common but temporary side effect of CAR-T therapy.
The safety profile is better than that of some of the FDA-approved CAR-T treatments, says Kekre. This could be related to the product, as well as to years of the scientific and medical community learning how to better care for patients, she says.
Humanizing the CAR probably contributed to the therapy’s positive safety profile, says Rahul Purwar, an immunologist at the Indian Institute of Technology Bombay, and founder of ImmunoACT. But others say that link has yet to be established.
Fry says the setting and type of patient treated in India could also affect the results. “The toxicity profile of CAR-T cells is driven by a lot of other patient factors.”
A member of the ImmunoACT team preparing the NexCAR19 cancer treatment.Credit: ImmunoACT
Slashing costs
Although the treatment’s price tag is still high for many Indians, whose annual gross national income per capita is less than $2,500, NexCAR19’s cost offers hope that CAR-T therapy can be made more cheaply in other countries and contexts. To slash costs, the team developed, tested and manufactured the product entirely in India, where labour is cheaper than in high-income countries.
To introduce CARs to T cells, researchers typically use lentiviruses, which are expensive. Purchasing enough lentiviral vector for a trial of 50 people can cost up to US$800,000 in the United States, says Steven Highfill, an immunologist at the US National Institutes of Health Clinical Center in Bethesda, who has advised the Indian team. Scientists at ImmunoACT make this gene-delivery vehicle themselves.
The Indian team also found a cheaper way to mass-produce the engineered cells, avoiding the need for expensive automated machinery, says Highfill.
Patients’ costs are further reduced by the therapy’s improved safety profile compared with some of the other FDA-approved products, Purwar says. This meant that most patients did not need to spend time in intensive-care units.
Purwar hopes to further cut costs, including by scaling up production. ImmunoACT is planning to export the therapy to Mexico, and to develop new products, including a treatment for another form of blood cancer known as multiple myeloma.
But ImmunoACT faces competition. Several other Indian companies have launched local CAR-T trials, including Immuneel Therapeutics in Bengaluru, which has licensed technology developed by Spanish academics.
If you are searching for reliable and high performance storage solutions for your video and photographic needs you might be interested to know that Lexar has this week added new additions to its professional storage range. The Professional CFexpress Type A Card SILVER Series and the Professional GOLD microSDXC UHS-II Card. These cards are a testament to Lexar’s commitment to providing cutting-edge technology for professionals who demand the best in performance and reliability.
Lexar Professional CFexpress Type A Card SILVER Series
Compatible with Sony Alpha and Sony FX cameras that support CFexpress Type A cards
Delivers max read speeds of 800 MB/s, max write speeds of 700 MB/s, and sustained write speeds of 600 MB/s
Video Performance Guarantee 200 (VPG200) ensures sustained write speed for seamless video capture with no dropped frames
Capture seamless 8K video and gorgeous burst-mode image
Lexar Professional GOLD microSDXC UHS-II Card
Accelerate workflow with transfer speeds up to 75% faster than UHS-I cards
Transfer massive amounts of high-res images with read speeds up to 280 MB/s
V60-rated to capture extended lengths of 4K video with no dropped frames
Quickly captures high-quality images with write speeds up to 180 MB/s
Also ideal for UHS-II portable gaming devices
Joey Lopez, Lexar’s Director of Marketing, emphasizes the importance of time efficiency for professionals. Lexar’s cards are designed not just for superior performance in capturing stunning visuals but also for rapid file transfers, enhancing workflow speed.
Pro CFexpress memory cards
SILVER Series
If you are a professional using Sony Alpha or Sony FX cameras, you’ll find the CFexpress Type A Card SILVER Series from Lexar to be a perfect match for your equipment. These cards are designed to cater to the high demands of modern photography and videography, offering maximum read speeds of up to 800 MB/s and write speeds of up to 700 MB/s. They are particularly adept at handling the rigors of 8K video capture and high-quality burst-mode photography, thanks to sustained write speeds of 600 MB/s.
The cards also come with a Video Performance Guarantee 200 (VPG200), ensuring a consistent write speed that is crucial for uninterrupted video recording and eliminating the worry of dropped frames. Available in 160 GB and 320 GB capacities, the SILVER Series is priced at $189.99 and $379.99, respectively. Lexar’s confidence in its product is reflected in the provision of a 10-year warranty, underlining the cards’ durability and reliability. This makes the SILVER Series a prudent investment for professionals seeking top-tier performance and peace of mind.
GOLD Series
For professionals who frequently use drones, action cameras, or portable gaming devices, Lexar’s GOLD microSDXC UHS-II Card emerges as an ideal storage solution. This card is specifically engineered to enhance your workflow, boasting read speeds of up to 280 MB/s. Such speed facilitates file transfers that are up to 75% faster compared to UHS-I cards, saving valuable time in high-paced environments.
Additionally, the card features impressive write speeds of up to 180 MB/s, along with a V60 rating. This combination is essential for capturing high-quality images and ensuring extensive 4K video recording without the inconvenience of dropped frames. Its versatility is further highlighted by its compatibility with a wide range of devices, including smartphones, gaming devices, and drones, making it a universally appealing choice for various professional needs.
The GOLD microSDXC UHS-II Cards are available in two sizes, 128 GB and 256 GB, with prices set at $39.99 and $74.99, respectively. This range offers flexibility in storage options to suit different requirements and budgets, making it a practical choice for professionals looking for reliable, high-performance memory solutions.
Lexar’s new Professional CFexpress Type A Card SILVER Series and GOLD microSDXC UHS-II Cards are more than just storage solutions. They are integral tools for professionals who value efficiency, quality, and reliability in their work. Whether capturing breathtaking 8K videos, engaging in high-speed photography, or seeking seamless gameplay, these cards are engineered to meet and exceed the demands of today’s digital creatives.
Filed Under: Camera News, Top News
Latest timeswonderful Deals
Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, timeswonderful may earn an affiliate commission. Learn about our Disclosure Policy.
Ventana Micro Systems as announced the introduction of its latest marvel in the Veyron lineup—the Veyron V2. Marketed as the highest performance RISC-V processor to date, it’s clear that Ventana has not only listened to its customer base but has also pushed the envelope in performance and efficiency. The Veyron V2, available as both chiplets and IP, is a testament to Ventana’s dedication to fostering rapid customer adoption through technological innovation.
40% Performance Gain
If you are wondering how Ventana has achieved this milestone, you will be pleased to know that a significant boost in the processor’s capabilities has been realized. With an impressive 40% surge in performance, the Veyron V2 is not just about speed; it’s about smarter, more efficient processing. This leap is attributed to a slew of microarchitecture enhancements, a state-of-the-art processor fabric architecture, and an expanded cache hierarchy, complete with a high-performance vector processor to top it off.
One can’t help but appreciate the strategic initiative known as RISE, which stands for RISC-V International Software Ecosystem. This program is instrumental in bolstering the support ecosystem, ensuring that Veyron V2 can swiftly roll out solutions that are open, scalable, and versatile.
From a business standpoint, the economic and temporal advantages are hard to ignore. Thanks to the industry-leading UCIe chiplet interconnect, Veyron V2 is not just a powerhouse but also a savvy economic choice. It offers a reduction in development costs by a staggering 75% and accelerates time to market by up to two years. It’s remarkable how chiplet-based solutions can provide such elasticity in computing, input/output, and memory configurations, allowing businesses to focus on their unique innovations and specialized workload optimizations.
In the realm of data centers, Ventana’s Domain Specific Accelerator technology works in concert with the Veyron V2 processor pipeline, enhancing efficiency across the board and fostering an environment ripe for customer-specific innovation. Industry experts, like Patrick Moorhead of Moor Insights & Strategy, believe that the cost-effective performance equation Ventana has achieved with the V2 chip may very well redefine benchmarks in high-performance computing.
Ventana Veyron V2
Let’s delve into the specs that make the Veyron V2 stand out. With a 3.6 GHz fifteen wide, aggressive out-of-order pipeline, and 32 cores per cluster, scalability is a breeze—up to 192 cores, to be exact. Add to that a generous 128 MB of shared L3 cache per cluster and a 512b vector unit, and you’ve got yourself a processor that doesn’t just perform, it excels.
For those interested in AI, the Veyron V2 comes equipped with Ventana AI matrix extensions, server-class IOMMU, and Advanced Interrupt Architecture (AIA) system IP. Additionally, advanced mitigations for side channel attacks and comprehensive RAS features ensure that performance is not only top-tier but also secure.
Features of the Veyron V2
Fifteen wide, aggressive out-of-order pipeline
3.6 GHz
4 nm process technology
32 cores per cluster
High core count multi-cluster scalability up to 192 cores
128 MB of shared L3 cache per cluster
512b vector unit
Ventana AI matrix extensions
Provided with server-class IOMMU and Advanced Interrupt Architecture (AIA) system IP
Advanced side channel attack mitigations
Comprehensive RAS features
Top-down performance tuning methodology
SDK released with necessary software already ported to Veyron
Veyron V2 Development Platform available
Software developers will find the provided SDK—a comprehensive set of software tools already proven on Ventana’s RISC-V platform—exceptionally useful. It simplifies the transition to Veyron, ensuring that software is already ported and ready to harness the full potential of the processor.
Ventana’s Veyron V2 is setting a new standard for RISC-V processors, and those interested should not miss the detailed technical presentation by Greg Favor, CTO of Ventana, at the RISC-V Summit North America 2023. It’s evident that this processor is poised to make a significant impact in the tech industry, offering unparalleled performance and efficiency that aligns with the needs of modern data centers, automotive, 5G, AI, and client applications.
Source : Ventana
Filed Under: Technology News, Top News
Latest timeswonderful Deals
Disclosure: Some of our articles include affiliate links. If you buy something through one of these links, timeswonderful may earn an affiliate commission. Learn about our Disclosure Policy.
Airway Physiotherapy (or “AirPhysio” for short) is a company that was formed in 2016 to treat people who have respiratory problems. We were aware that many people have comparable complaints and that natural therapeutic devices, while available, were generally unknown and needed to be updated.
We set out to develop a cutting-edge substitute for existing market offerings. The current devices are effective, but after consulting with many physicians and patients, we recognized that only some with these disorders could benefit from them, and many patients needed to fully understand their condition or what was going on with their lungs. We conducted extensive research into many of these conditions, compiling both scientific papers and simplified information about what was going on, how current treatments were assisting, and which states required additional support from OPEP devices like the AirPhysio device to reverse the decline in lung function caused by these conditions.
We’ve since begun a program to educate the public about their sickness and how to care for them better. She appeared on shows like Modern Living with Kathy Ireland (7 News) and other media to motivate others to change their lives significantly.
More About AirPhysio
AirPhysio is a mucus clearance and respiratory physiotherapy device that helps athletes and other physically active persons by increasing lung capacity, minimizing shortness of breath during exercise, increasing exercise tolerance, and shortening recovery times.
The AirPhysio device and the business that produced it, AirPhysio, have received numerous national and international accolades.
What Is Airphysio?
AirPhysio is a cutting-edge cutting-edge answer to your snoring problems. It can help you stop snoring by thinning and expanding the mucus in your lungs. This advanced technology will allow you to breathe soundlessly by cleaning out the chest congestion. After a few days of utilizing it, you’ll feel more at peace and comfortable. Because AirPhysio addresses the fundamental cause of your snoring, you and your partner will get a good night’s sleep every time you use it. Airphysio’s design has no adverse effects or drug-like properties. It also has no long-term harmful repercussions. This breakthrough new technology removes the heavy mucus that builds up in the lungs, decreasing snoring, which affects sleep for many individuals.
Anyone experiencing breathing issues, whether temporary or chronic, seasonal or due to a severe case of the common cold, may benefit from utilizing AirPhysio.
The device is valid even if you don’t snore since it helps clean your airways. It is entirely risk-free to use. However, the AirPhysio’s use goes beyond simply assisting the quick and natural discharge of thick, sticky mucus. People can recover from the illness more quickly because of AirPhysio’s successful work in improving their lungs and airways.
Respiratory Conditions
AirPhysio can be used in conjunction with medical treatment or as a natural approach to treating respiratory disorders such as Asthma, Bronchiectasis, COPD, and Cystic Fibrosis.
How Smokers Lose Lung Function Without Realizing It.
Why is breathing becoming more difficult as I get older?
Removal of Pollutants from the Body and alongside How Pollution Affects this Process.
Pollution from Occupational Dust and Particle Matter.
How Does AirPhysio Work?
Airphysio is a reliable and simple alternative to the OPEP device. Use the Airphysio for 10 minutes before going to bed if you snore. A sufficient amount of airflow is required, and functioning may be confirmed by watching the ball bearing inside the glass cap rise. Because of the increased pressure within the lungs, the mucus that causes snoring is ejected from behind the lungs. The following surge in intrapulmonary pressure causes mucus to be expelled from behind the lungs.
As the mucus goes up the throat, it can be expelled by coughing. The minimum number of times this operation should be repeated is ten. The mucus in your lungs will be removed. It is beneficial to your lungs. Following that, many visitors sought refuge on the main page. If that’s the case, your lungs are getting better. In contrast to an inhaler used for inhaling, the AirPhysio is used for exhalation and must be held firmly to the lips. Routine breathing can be restored by coughing vigorously to remove mucus from the lungs.
Do you have a painful throat daily because of the heavy mucus accumulated overnight? Do you have breathing issues due to a previous ailment, and do you visit the doctor frequently and buy medication to help? Or have you suffered due to the normal narrowing of your airways as you age?
The AirPhysio is the ideal solution for you. Using this item daily helps strengthen and widen your airways, allowing for easier breathing. If you’re looking for a place to get an AirPhysio, we recommend visiting the company’s official website since they routinely offer deals and promotions at steep discounts.
How To Use Air Physio?
You may rest easy knowing that the Food and Drug Administration has approved Air Physio. Numerous lab investigations have been conducted to establish its safety, and medical authorities recommend it. It is only natural to avoid using medicines and other artificial techniques to stop snoring. You’ll be able to take longer, deeper breaths and feel more alert. Don’t be alarmed if you feel a tickle in your throat or want to cough after blowing through the tube; these feelings are normal and are your body’s way of removing mucus from your airways.
For optimal efficiency, use Airphyio many times each day. If you need to nap throughout the day, try air physio before you fall asleep. If you use it regularly and consistently, you will notice a significant increase in your lung capacity and overall health.
Benefits
Try using air physio to get a good night’s sleep:
Snoring is the most prevalent concern between spouses. At this hour, many men are sleeping. Air physiotherapists have created a terrific solution to stop snoring. You and your partner may discover that utilizing Air Physio helps you sleep better at night. Many people regard the approach used in Air Physio as a miracle because it is a natural gadget with no harmful side effects or animal testing. Simply taking several deep breaths of air before going to bed will help your body sleep better. You may be able to relax after around two weeks of therapy completion.
It was designed with complete security in mind:
There are a variety of snoring sprays and chemical remedies on the market today, but air physio is an all-natural approach. This product works with little more than a deep inhale. Many scientists support this chemical, which has also been tested and shown to be helpful in clinical settings.
You’ll see results in minutes:
Air physio, unlike rival products, genuinely works. You’ll receive your answers in a matter of minutes. Just a few deep breaths of air before bedtime will help you drift off to sleep. Most consumers report a significant improvement after beginning to use Air Physio.
Snoring may make you feel like you’re attempting to sleep while breathing through a tiny straw. Imagine yourself free of the straw, your breathing becoming more natural and effortless.
When mucus builds up too much, it might clog your airways, but AirPhysio can help clear it. The gentle pressure pulses immediately remove partly obstructed airways. This all-natural remedy gets to the base of the snoring problem, allowing you to sleep better.
What are the Essential Features of AirPhysio?
AirPhysio is made up of the following components and accessories:
Circular cone
Stainless steel ball
Child-resistant protective cover
Mouthpiece and base
Mouthpiece cap
AirPhysio can be used with a gradually smaller or bigger steel ball, depending on the user’s age and tolerance for airway resistance.
The smaller steel ball provides less expiratory resistance, making it an excellent alternative for younger patients and those with weakened respiratory systems.
A regular-sized steel ball is the best option for those in excellent health who are physically active yet have mild to severe respiratory difficulties.
What are the Contraindications?
Contraindications: Consumers are advised to visit their doctors/healthcare professionals if they are suffering from, or are unclear if they are suffering from, any of the following conditions:
Right-sided heart failure
Untreated pneumothora
Oesophageal surgery
Tuberculosis
Middle ear pathology, such as ruptured tympanic membrane.
